Directory Search
ABCAM
Abcam’s purpose is to serve life science researchers globally to achieve their mission, faster. Abcam offers highly validated antibodies and assays to address important targets in critical biological pathways. A transparent programme of customer reviews, datasheets and an industry-leading Knockout validation initiative, gives researchers increased confidence in their results
| Website: | http://www.abcam.com |
| Email: | au.orders@abcam.com |
| Phone: | 1800 024 968 |
| Fax: | (03) 8400 4333 |
| Address: |
Products
Abcam knockout cell lines and lysates
CRISPR-Cas9 knockout cell lines from Abcam provide scientists with off-the-shelf, single-gene knockouts so the user can confidently interrogate the relationship between genotype and phenotype without having to establish their own knockout cell line.Abcam engineered knockout cell lysates
Abcam's engineered knockout cell lysates enable proteomic studies by providing researchers with 'true negative' controls.Abcam tissue clearing kits and reagents for 3D imaging
Abcam's tissue clearing kits and reagents enable easy and rapid clearing for 3D imaging of tissues and cell culture models.
Abcam CatchPoint SimpleStep ELISA kits
CatchPoint SimpleStep ELISA kits have been developed using a fluorescent substrate to provide improved linearity over an extended dynamic range when compared to TMB substrate.Abcam FirePlex-HT multiplex immunoassays
Abcam's FirePlex-HT immunoassays offer a no-wash workflow in 384-well plate format, enabling multiplex quantification of up to 10 protein analytes per well from as little as 6.25 µL of plasma, serum or cell culture supernatant.Abcam RabMAb recombinant rabbit monoclonal antibodies
Abcam has combined the advantages of its RabMAb rabbit monoclonals with recombinant technology to deliver high-performance antibodies.Abcam knockout-validated antibodies
With the increasing need for highly specific antibodies, Abcam introduces KO validation as a standard quality control protocol for antibodies at scale.News
Abcam purchases assets from Applied StemCell
Abcam has announced the asset purchase of the gene editing platform and oncology product portfolio of Applied StemCell for life science research and diagnostic markets.Abcam acquires Expedeon's Proteomics and Immunology business
Abcam has announced the successful completion of the acquisition of Expedeon's Proteomics and Immunology business, which includes Innova and TGR Biosciences, as of 1 January 2020.Abcam acquires live cells and lysates from EdiGene
Abcam has announced its acquisition of the entire live cell line and lysates portfolio of EdiGene, a Chinese company focused on developing genome editing technologies into novel therapeutics.NanoString and Abcam enter partnership to expand antibody portfolio
NanoString Technologies has announced a commercial agreement with Abcam for the manufacture and sale of antibodies specifically for use with NanoString's GeoMx Digital Spatial Profiler (DSP).White Papers
How to raise antibody standards and improve reproducibility
Currently 70% of researchers fail to reproduce experiments. With so much research built on previous work, our scope for scientific discovery is significantly limited.
